Lausch Karen Rokkedal, Søgaard Mette, Rosenvinge Flemming Schønning, Johansen Helle Krogh, Boysen Trine, Røder Bent Løwe, Mortensen Klaus Leth, Nielsen Lene, Lemming Lars, Olesen Bente, Leitz Christine, Kristensen Lise, Dzajic Esad, Østergaard Lars Jørgen, Schønheyder Henrik Carl, Arendrup Maiken Cavling
Department of Infectious Disease, Aarhus University Hospital, 8200 Aarhus, Denmark,
Department of Cardiology, Aalborg University Hospital, 9000 Aalborg, Denmark.
Infect Drug Resist. 2018 Nov 23;11:2449-2459. doi: 10.2147/IDR.S176384. eCollection 2018.
In accordance with international guidelines, primary antifungal treatment (AFT) of candidemia with echinocandins has been nationally recommended in Denmark since 2009. Our nationwide cohort study describes the management of candidemia treatment focusing on the impact of prophylactic AFT on species distribution, the rate of adherence to the recommended national guidelines for AFT, and the effect of AFT on patient outcomes.
Incident candidemia cases from a 2-year period, 2010-2011, were included. Information on AFT was retrospectively collected from patient charts. Vital status was obtained from the Danish Civil Registration System. HRs of mortality were reported with 95% CIs using Cox regression.
A total of 841 candidemia patients was identified. Prior to candidemia diagnosis, 19.3% of patients received AFT (162/841). The risk of non- candidemia increased after prior AFT (59.3% vs 45.5% among nontreated). Echinocandins as primary AFT were given for 44.2% (302/683) of patients. Primary treatment with echinocandins resulted in adequate treatment in a higher proportion of patients (97.7% vs 72.1%) and was associated with lower 0- to 14-day mortality compared with azole treatment (adj. HR 0.76, 95% CI: 0.55-1.06). Significantly lower 0- to 14-day mortality was observed for patients with and with echinocandin treatment compared with azole treatment (adj. HR 0.50, 95% CI: 0.28-0.89), but not for patients with or .
The association shown between prior AFT and non- species underlines the importance of treatment history when selecting treatment for candidemia. Compliance with national recommendations was low, but similar to previously reported international rates. Primary treatment of candidemia with echinocandins compared with azoles yielded both a higher proportion of adequately treated patients and improved mortality rates. This real-life setting supports guidelines recommendation, and further focus on compliance with these seems warranted.
根据国际指南,自2009年起丹麦全国推荐使用棘白菌素进行念珠菌血症的初始抗真菌治疗(AFT)。我们的全国队列研究描述了念珠菌血症治疗的管理情况,重点关注预防性AFT对菌种分布的影响、对推荐的全国AFT指南的依从率以及AFT对患者结局的影响。
纳入2010年至2011年这两年间的新发念珠菌血症病例。从患者病历中回顾性收集有关AFT的信息。生命状态信息来自丹麦民事登记系统。使用Cox回归报告死亡率的风险比(HR)及95%置信区间(CI)。
共确定了841例念珠菌血症患者。在念珠菌血症诊断之前,19.3%的患者接受了AFT(162/841)。在接受过AFT的患者中,非念珠菌血症的风险增加(未治疗患者中为45.5%,接受过AFT的患者中为59.3%)。44.2%(302/683)的患者使用棘白菌素作为初始AFT。与唑类治疗相比,使用棘白菌素进行初始治疗使更高比例的患者得到充分治疗(97.7%对72.1%),并且与较低的0至14天死亡率相关(校正HR 0.76,95% CI:0.55 - 1.06)。与唑类治疗相比,使用棘白菌素治疗的 和 患者观察到显著更低的0至14天死亡率(校正HR 0.50,95% CI:0.28 - 0.89),但 或 患者未观察到这种情况。
先前的AFT与非 菌种之间的关联强调了在选择念珠菌血症治疗方法时治疗史的重要性。对国家建议的依从性较低,但与先前报道的国际比率相似。与唑类相比,使用棘白菌素对念珠菌血症进行初始治疗可使更高比例的患者得到充分治疗,并提高死亡率。这种实际情况支持指南推荐,似乎有必要进一步关注对这些指南的依从性。